Want to see CERS full AI Analyst Report?
CERS Stock Chart & Stats
$2.72
$0.06(2.09%)
At close: 4:00 PM EDT
$2.72
$0.06(2.09%)
Day’s Range― - ―
52-Week Range$1.38 - $3.47
Previous CloseN/A
Volume2.51M
Average Volume (3M)1.84M
Market Cap
$481.64M
Enterprise Value$606.88M
Total Cash (Recent Filing)$56.26M
Total Debt (Recent Filing)$76.80M
Price to Earnings (P/E)―
Beta1.86
Next Earnings
Nov 02, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding201,524,900
10 Day Avg. Volume1,803,906
30 Day Avg. Volume1,837,441
Financial Highlights & Ratios
PEG Ratio0.99
Price to Book (P/B)6.11
Price to Sales (P/S)1.90
P/FCF Ratio46.07
Enterprise Value/Market Cap1.26
Enterprise Value/Revenue2.74
Enterprise Value/Gross Profit5.26
Enterprise Value/Ebitda208.69
Forecast
1Y Price Target
$4.50Price Target Upside65.44% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.05
Revenue Forecast (FY)$255.05M
Bulls Say, Bears Say
Bulls Say
Product Revenue Growth And Raised GuidanceDouble-digit product growth across the first half and higher full-year guidance indicate continuing demand for Cerus’s core blood-safety offerings. Sustained expansion can increase the installed customer base, support recurring consumables revenue, and improve operating leverage as volume scales.
Recurring Consumables Business ModelThe consumable nature of INTERCEPT processing creates repeat revenue linked to ongoing blood-component treatment rather than only one-time equipment sales. This model can strengthen customer retention, improve revenue visibility, and provide a durable foundation as pathogen-reduction use expands.
Regulatory And Product Pipeline ProgressAdvancing INT200 toward potential FDA approval and progressing INTERCEPT RBC clinical testing broaden Cerus’s future product opportunity beyond its current offerings. Successful regulatory and clinical execution could expand addressable blood components and reinforce its position in transfusion safety.
Bears Say
Ongoing GAAP LossesCerus has improved its losses and delivered positive adjusted EBITDA, but it remains GAAP unprofitable. Continued net losses limit internally generated capital, make sustainable earnings less certain, and leave the company more dependent on operating improvement to fund expansion and development.
Elevated LeverageDebt materially exceeds equity, so interest obligations and financing requirements remain important constraints on financial flexibility. Although refinancing reduced the term loan and may lower interest expense, elevated leverage can restrict investment capacity and increase sensitivity to weaker operating performance.
Weak Cash Conversion And Margin PressureRecent cash generation has not consistently matched the company’s improving operating results, with TTM free cash flow slightly negative. Lower expected gross margins and inventory investment could further delay reliable cash conversion, limiting the resources available for debt reduction and growth initiatives.
Cerus News
CERS FAQ
What was Cerus Corp’s price range in the past 12 months?
Cerus Corp lowest stock price was $1.38 and its highest was $3.47 in the past 12 months.
What is Cerus Corp’s market cap?
Cerus Corp’s market cap is $481.64M.
When is Cerus Corp’s upcoming earnings report date?
Cerus Corp’s upcoming earnings report date is Nov 02, 2026 which is in 10 days.
How were Cerus Corp’s earnings last quarter?
Cerus Corp released its earnings results on Jul 30, 2026. The company reported -$0.01 earnings per share for the quarter, beating the consensus estimate of -$0.013 by $0.003.
Is Cerus Corp overvalued?
According to Wall Street analysts Cerus Corp’s price is currently Undervalued.
Does Cerus Corp pay dividends?
Cerus Corp does not currently pay dividends.
What is Cerus Corp’s EPS estimate?
Cerus Corp’s EPS estimate is -0.01.
How many shares outstanding does Cerus Corp have?
Cerus Corp has 201,524,900 shares outstanding.
What happened to Cerus Corp’s price movement after its last earnings report?
Cerus Corp reported an EPS of -$0.01 in its last earnings report, beating expectations of -$0.013. Following the earnings report the stock price went down -25.606%.
Which hedge fund is a major shareholder of Cerus Corp?
Currently, no hedge funds are holding shares in CERS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cerus Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.50 (65.44% Upside)
$4.50 (65.44% Upside)
Blogger Sentiment
Bullish
CERS Sentiment 100%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 5.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 0.1%
Last 30 Days ▲ 0.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
45.73%
12-Months-Change
Fundamentals
Return on Equity
-10.31%
Trailing 12-Months
Asset Growth
-3.70%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Cerus Corp
Cerus Corporation operates as a biotechnology firm dedicated to advancing and marketing the INTERCEPT Blood System. This proprietary technology significantly enhances the safety of transfusable blood components by neutralizing biological threats, thereby reducing the risk of blood-borne pathogens. The company's product line includes INTERCEPT systems specifically engineered to deactivate pathogens in donated platelets and plasma. It also offers a dedicated INTERCEPT Blood System for the inactivation of harmful agents in red blood cell components. Furthermore, Cerus markets an INTERCEPT Blood System for Cryoprecipitation, which leverages its plasma technology to produce two key pathogen-reduced blood products: a cryoprecipitated fibrinogen complex for treating and controlling bleeding, particularly massive hemorrhages stemming from fibrinogen deficiency, and pathogen-reduced, cryoprecipitate-reduced plasma. Cerus distributes these platelet and plasma systems globally through a combination of its direct sales force and an extensive network of distributors, reaching markets in North America, Europe, the Commonwealth of Independent States, the Middle East, and Latin America. Established in 1991, Cerus Corporation maintains its corporate headquarters in Concord, California.
CERS Company Deck
CERS Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed predominantly positive momentum: double-digit product revenue growth, raised product and IFC guidance, consecutive quarters of positive adjusted EBITDA, meaningful debt refinancing benefits, regulatory progress (PMA submission and upcoming Phase 3 readout), and a clean quality audit. Counterbalancing items include a drop in gross margin (51.4% vs 55.2% prior year) driven by currency and inflationary pressures, reduced government contract revenue this quarter, modest operating cash use for inventory, and regulatory/penetration challenges in Asia-Pacific and for broader IFC adoption. On balance the positives (top-line growth, improving profitability measures, stronger balance sheet flexibility, and regulatory/clinical progress) outweigh the near-term headwinds.View all CERS earnings summariesCERS Stock 12 Month Forecast
Average Price Target
$4.50
▲(65.44% Upside)
Technical Analysis
Tactile Systems Technology
―
Viemed Healthcare
―
Brainsway
―
Outset Medical
―
908 Devices
―
Ownership Overview
5.71% Insiders
12.85% Mutual Funds
1.46% Other Institutional Investors
58.55% Public Companies and
Individual Investors